Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib Added to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
2014-001287-35Phase 2Terminated
- Sponsor
- Clínica Universidad de Navarra
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vismodegib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Clínica Universidad de Navarra. Primary endpoint: Safety and tolerability of vismodegib in combination with neoadjuvant chemotherapy. Started Nov 2014; status: terminated.
02
Drugs
vismodegib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2014-001287-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001287-35.